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Kay E. Davies2,*I would like to begin by thanking Gene Fisch for his very
generous introduction. This award is a great honor and is
testament to the many talented students and research fel-
lows who have worked withme over the years. I would also
like to acknowledge my mentors, who introduced me to
genetics for the first time 35 years ago. I am very grateful
to the many friends and collaborators who have debated
with me long into the night on the best ways forward at
many genetics meetings. The ASHG meetings have always
been special to me as I watched the society keep pace with
the ever-changing field of genetics both in research and in
delivery to the patient. Finally, I would like to thank my
family, who have supported me at all points in my career,
even when they were not sure where the next steps were
taking me!
Over the last 30 years, I have participated in an extra-
ordinary journey from the isolation of fragments of the
X chromosome for the diagnosis and carrier detection of
X-linked disorders to the development of therapies for
Duchenne muscular dystrophy (DMD), but first let me
give a bit of personal history.
I never thought for one moment that I would have the
opportunities I have had in genetics. I studied chemistry
at Oxford and had never studied biology at school because
the timetable did not allow it. I needed Latin to get into
Oxford, and therefore that took precedent. At Oxford I
was very much inspired by Dorothy Hodgkin, who was a
fellow at my college, Somerville. She was still active in
the 1970s and attended one of my early lectures. Somer-
ville has many famous alumni: Margaret Thatcher also
studied chemistry there, which shows that such a back-
ground is a good training for anything! (Incidentally,1This article is based on the address given by the author at the meeting of T
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studied chemistry, so maybe this is good training for
leadership.)
My studies for my Ph.D. focused on chromatin structure
in the era before nucleosomes had been described, and this
gave me a good grounding in protein biochemistry. This
led to the French laboratory of Andre´ Sentenac, who was
cloning RNA polymerase genes from yeast. This was my
first encounter with genetics, and I was immediately
hooked. Once the paper from Y.W. Kan’s laboratory on
the diagnosis of sickle cell anemia came out,1 the appli-
cation of restriction-fragment-length polymorphisms
(RFLPs) to the localization of disease genes was proposed
by Botstein and colleagues.2 The potential of this new ge-
netics for the diagnosis of disease as well as the identifica-
tion of disease genes was obvious. I was invited to join the
laboratory of Bob Williamson in London; he was already
ahead in his thinking on the application of this new ge-
netics to human disease because of his interest in cystic
fibrosis. However, he recognized that it was better to focus
on a disease where the chromosomal localization of the
gene was known, such as X-linked DMD, because we
were not sure that there would be sufficient variation in
the genome for mapping all diseases. DMD is a devastating
X-linked recessive disorder characterized by progressive
muscle wasting and weakness. Patients are typically wheel-
chair bound by age 12 and die from respiratory failure or
cardiomyopathy in their 20s.3,4 When we began this
work, no prenatal diagnosis was available, the carrier test
was unreliable, and there was no effective treatment.5
The only clue to the localization of the gene was the exis-
tence of females with balanced X-autosome translocations
with breakpoints in Xp21, and there was a need for
X-linked markers for mapping X-linked diseases. Impor-
tantly, the Cystic Fibrosis Trust, which had funded the
group to collect blood samples from all cystic fibrosis
(CF) patients in the UK and funded my fellowship, also
showed great foresight and backed this scientific rationale.
Our first objective was to make a library of highly en-
riched sequences for the X chromosome as a potential
source of DNA probes that we could develop as RFLP
probes. This required the sorting of chromosomes from a
48XXXX cell line in Glasgow with Bryan Young, who
was setting up this technique for chromosome 22.6he American Society of Human Genetics (ASHG) on October 9, 2015, in
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It was an arduous task in those days to focus fluo-
rescence-activated cell sorting (FACS) to deflect the chro-
mosomes that we wanted, and very often this required
adjusting the cathode oscilloscope by hand and working
into the early hours. The small amounts of DNA were ex-
tracted from the chromosomes and then cloned into phage
libraries for further study. The localization of the sequences
was confirmed with somatic cell hybrid cell lines that con-
tained different fragments of the X chromosome. Such
lines were derived from work in Hilger Roper’s laboratory,
which supplied the DNA. We eventually managed to iden-
tify enough sequences distributed randomly along the
chromosome to generate the first genetic map of the hu-
man chromosome at 10 cM intervals with Ray White and
Dennis Drayna and colleagues.7 We were not alone in
this work: Louis Kunkel in Sam Latt’s laboratory had also
cloned an X-chromosome-enriched library, and Peter Pear-
son together with Gert jan van Ommen had produced
other key markers for the localization of the DMD gene
(see Guiraud et al.5 for a review).
It was at this point that I met DMD patients and their
families for the first time as we began to work closely
with them. I was inspired by their courage and confidence
in us, and we were persuaded by the muscular dystrophy
charities in the UK and US (the Muscular Dystrophy
Campaign and Muscular Dystrophy Association, respec-
tively) to take on the challenge of finding the disease
gene. I realized the enormous unmet clinical need for an
accurate test and an effective treatment. I was to dedicate
my academic career to meet this need, and we are almost
there.
For the mapping of the DMD locus, we focused on
markers around Xp21 because of the female translocations
suggesting that the gene might lie in this region. We were
very fortunate to collaborate with Peter Harper’s group
because they had collected clinically well-characterized
DMD-affected families. In 1981, we produced the first
markers that localized DMD to Xp21 and used flanking
markers for prenatal diagnosis of the disease.8 Peter Harper
and colleagues used these markers to show that Becker
muscular dystrophy (BMD), which has a muchmilder clin-
ical course, was likely to be allelic.9 It is interesting to note
that it could take up to 3 weeks to complete these diag-
nostic tests by Southern blots, whereas now the same tests
can be completed within hours via PCR. It was also the
time when chorion villus sampling was being developed
for prenatal diagnosis. Bob arranged collaboration with
Charles Roedeck, who pioneered this technique, and one
of our first diagnoses was of a twin pregnancy. Fortunately,
this turned out to be a boy and a girl, so we could easily
confirm the diagnosis that this apparently normal preg-
nancy was not the result of sampling the same twin twice!
At this time, Bob Williamson returned to the identifica-
tion of the CF gene, and I pursued the DMD gene at the
Institute of Molecular Medicine at Oxford, where I was
fortunate to be mentored by David Weatherall, a leader
in the study of thalassaemia. It was very inspiring to420 The American Journal of Human Genetics 98, 419–426, March 3work alongside such an eminent academic clinician who
attracted so many other young scientists such as myself
at the interface of basic science and medicine.
The DMD gene was eventually identified by two inde-
pendent strategies. Louis Kunkel identified the gene by tak-
ing advantage of a deletion seen in a patient suffering from
DMD,10 chronic granulomatous disease, and retinitis pig-
mentosa in Xp21, first reported by Uta Franke.11 RonWor-
ton’s group identified the gene through the cloning of the
breakpoint in a female suffering from DMD with a break-
point in Xp21 and the rRNA genes on chromosome 21.12
This was an exciting time for diagnosis, and these groups
made probes to facilitate prenatal diagnosis and carrier
testing as soon as they became available. Using these
markers, my group showed that although the DMD gene
showed a high rate of deletion, there were two hotspots
for deletion.13 These hotspots are now well characterized
and have enabled many mutations in the gene to be diag-
nosed with a relatively small number of probes.14 Monaco
et al.15 also demonstrated that BMD patients are mildly
affected because the deletions do not destroy the reading
frame of the mRNA, and therefore a truncated, partially
functional protein is produced.
The DMD gene turned out to be remarkable: not only is
it encoded by a large 14 kb mRNA, but the coding region is
also spread over more than 2 Mb of DNA. The large extent
of the gene was established by my group16 and by workers
in Holland and Germany17,18 with the use of pulsed-field
electrophoresis, which showed that very large deletions
(1–2 Mb) could be seen in patients who suffered from
only DMD. Further refined mapping of the gene showed
that it consists of 79 exons spread over more than 2 Mb
of DNA and that some introns cover more than 200 kb.
Thus, the high mutation rate for DMD can be explained
by its large size. However, as of yet there is no explanation
for why there is such a high rate of deletion or why these
occur predominantly in two regions within the gene.
Elegant work from the Kunkel laboratory showed that
the gene encodes a 427 kD structural protein (named dys-
trophin because its loss results in muscular dystrophy)
localized at the sarcolemma.19,20 The groups of Campbell
and Ozawa showed that dystrophin is bound to a complex
of proteins that link the extracellular matrix via laminin to
the internal cytoskeleton via actin.21–23 In the absence of
dystrophin, the sarcolemma becomes more susceptible to
contraction-induced injury, resulting in continual muscle
regeneration and necrosis, leading to myofiber loss.
Through the characterization of deletions in patients, we
demonstrated that a mild phenotype is compatible with
large deletions of the central rod domain of the DMD pro-
tein, dystrophin.24 The late Sarah Bundey sent us a sample
from one of her patients who presented with a particularly
mild form of BMD. He had served in the army and not
shown any symptoms until his 40s. Characterization of
his deletion showed that, surprisingly, 46% of the region
coding for the central rod domain was deleted. Our hy-
pothesis was that the mild presentation could be the result, 2016
of some compensatory gene in his genome or that this
minigene was partially functional. One of the patient’s rel-
atives had the same deletion and was also mildly affected,
arguing for the latter scenario.We tested this hypothesis by
reconstructing his gene as a transgene under the control of
the skeletal actin promoter and expressing it in the mdx
mouse model of the disease.25 The minigene was able to
prevent the pathology in this mouse model. Thus, in spite
of some initial skepticism, it was shown that minigenes,
modeled on these large deletions, function as a replace-
ment for the missing gene.25 This dystrophin minigene
has been distributed worldwide and is used as the basis
for numerous gene-therapy protocols, and further develop-
ment of microdystrophin genes is being introduced into
current gene-therapy paradigms.26,27
As part of our work on the identification of gene dele-
tions, we screened our fetal-muscle cDNA library with frag-
ments of the gene to isolate further coding fragments. One
of these cDNA fragments gave a strong signal in the screen,
but it did not map to any of the X chromosome fragments
in our somatic cell hybrid lines. Here, we were fortunate to
have Diane Hill, who ran the sequencing facility in Dune-
din, New Zealand, visit the laboratory. We were very
excited when we obtained the sequence: the cDNA was
indeed different from dystrophin cDNA, but it was also
remarkably similar. We had identified an autosomal
paralog of dystrophin.28 We went on to show that this
gene is localized on human chromosome 6 and encodes
a 13 kb mRNA, which is also spread over many exons in
an arrangement very similar to that of the exons in the
dystrophin gene (approximately 1 Mb).29 We called the
protein utrophin because unlike dystrophin, whose
expression is confined to muscle and the brain, utrophin
is expressed in most tissues.30,31 Like dystrophin, utrophin
is a large cytoskeletal protein (394 kDa)32 but is only ex-
pressed in small amounts in adult muscle.33 Their genomic
structures are similar,34 which suggests that dystrophin
and utrophin are related by an ancestral duplication event,
although which gene came first is unknown. Our labora-
tory was the first to clearly suppose that utrophin might
be capable of performing the same cellular functions as
dystrophin and be used as a surrogate for DMD.35
Our studies of the localization of utrophin in muscle
showed that it is found at the sarcolemma in utero and is
progressively replaced by dystrophin during develop-
ment.36–38 In adults, utrophin is enriched in skeletalmuscle
at theneuromuscular andmyotendinous junctions31 andat
the sarcolemma in regenerating myofibers.39 In DMD pa-
tients, utrophin spreads to the sarcolemma, but we demon-
strated that this was likely to be stabilization of the protein
rather than transcriptional upregulation of the gene.40
In view of the high homology between the genomic
sequences, we characterized the promoter regions of the
two genes. Dystrophin has five promoters that drive its
expression in skeletal muscle, the heart, and the brain.41
The dystrophin locus also expresses smaller isoforms that
encode the C-terminal region. Utrophin has smaller iso-The Ameforms encoding the C-terminal regions in a similar way,
but the 50 controlling region of the full-length gene is quite
different. Significantly, the utrophin gene has a CpG island
in the 50 region, and an N-box is responsible for the expres-
sion of utrophin at the synapse. The N-box is a 6 bp motif
first characterized by Changeux and colleagues and shown
to be very important for the expression of the acetylcho-
line receptor at the synapse.42 Mutation of this N-Box
motif at the 50 end of the utrophin gene results in the ex-
tra-synaptic expression of the protein.43 Thus, the reason
for the different localizations of dystrophin and utrophin
lies partly in their transcriptional control.
We reasoned that since themain difference between dys-
trophin and utrophin lies in their regulation, utrophin
should be able to compensate for the lack of dystrophin
in DMD if it is expressed at high enough levels in the mus-
cles of patients. This is supported by the fact that dystro-
phin and utrophin are found at the sarcolemma together
in early human fetal life, as mentioned earlier.36 We tested
this hypothesis in themdxmouse model of DMD by gener-
ating transgenic mice expressing utrophin under the con-
trol of the skeletal-muscle actin promoter. The utrophin
was able to prevent the pathology of the mdx mouse in a
dose-dependent manner.44 We went on to suggest that
the upregulation of the expression of the utrophin gene
would produce a clinical effect.
At this stage, it was important to elucidate the function
of utrophin in muscle. If we were to increase the levels of
utrophin, would this disturb other functions? Our labo-
ratory also enhanced the understanding of utrophin
function through gene-knockout technology. The utro-
phin-deficient mouse shows mild reduction at the neuro-
muscular junction, demonstrating that utrophin functions
not in the formation of acetylcholine receptor clusters but
rather in the stabilization of such clusters.45 This mouse
showed no other symptoms, suggesting that it does not
play a major role in muscle or other tissues. We also sug-
gested that the mdx and utrophin-deficient mice might
be relatively mildly affected given that dystrophin and
utrophin could compensate functionally. We validated
this by generating a double mutant lacking both dystro-
phin and utrophin.46 This double-knockout mouse suffers
a severe progressive muscular dystrophy much more like
the severe clinical course seen in DMD patients and dies
at 20 weeks. This model has been used as a more stringent
model for preclinical studies. For example, we have shown
that the severe phenotype can be prevented by administra-
tion of snRNAAV constructs containing sequences that
promote the skipping of the stop codon in exon 23 of
the gene in the mdx mouse.47
Recent studies have shown that although it is similar to
dystrophin, utrophin cannot anchor nNOS to the sarco-
lemma.48 Nevertheless, it is important to note that BMD
patients who lack the nNOS binding site are often mildly
affected, and therefore the lack of nNOS binding might
not be very significant.24 This could also be compensated
by treatment with PDE5 inhibitors, such as tadalafil.49,50rican Journal of Human Genetics 98, 419–426, March 3, 2016 421
Utrophin also does not interact with microtubules in the
same way that dystrophin does51 and therefore might
not prevent microtubule-lattice derangement, potentially
leading to aberrant calcium regulation and increased reac-
tive oxygen species.52,53 Despite these subtle differences, as
described by our lab and others, utrophin can act as a sur-
rogate for dystrophin in dystrophic muscles.54–56 In the
mdx mouse, the utrophin A isoform, found at the neuro-
muscular junction, is naturally increased (1.8-fold) as a
part of the natural repair process in the absence of dystro-
phin. This repair mechanism also occurs in DMD pa-
tients.57–59 Increasing utrophin A expression up to 2- to
4-fold more than the wild-type level prevents the develop-
ment of pathology in the mdx mouse.44,60 Importantly,
this increased level of utrophin is significantly less than
the normal levels found in the kidney and liver44 and is
not toxic in a broad range of murine tissues.61 Neverthe-
less, the actual levels of dystrophin or utrophin needed
to provide functional clinical benefits are still unknown
whatever the approach used. Previous work has indicated
that approximately 20% of wild-type dystrophin levels
are required for a significant correction of the muscle pa-
thology.62 However, an increase in dystrophin to 4% of
wild-type levels in the mdx mouse is sufficient to increase
survival, suggesting that lower levels might be beneficial
in humans.63 We would therefore anticipate that similar
sub-normal levels of utrophin would show a benefit.
There are several advantages of utrophin-modulation
therapy: increased utrophin levels will be applicable to
all DMD patients regardless of the dystrophin mutation
and do not appear to be toxic.61 Furthermore, a systemic
strategy designed to increase the endogenous utrophin
level to treat all types of muscle, including the heart and
diaphragm, will not result in an immune response. Strate-
gies to increase utrophin levels include direct delivery of
the protein64 or stabilization of the protein or RNA,65,66
viral approaches,67,68 and non-viral approaches such as bi-
glycan.69 We have shown that oral administration of small
molecules designed to modulate utrophin expression at
the transcriptional level can decrease the progression of
the disease in the mdx mouse and represents a promising
therapeutic avenue for DMD.70 An effective small mole-
cule to modulate utrophin expression should target skel-
etal and cardiac muscle and result in an increase in the
localization of utrophin throughout the myofibers.
Over the last 3 years, we have made considerable prog-
ress toward the goal of utrophin modulation by using
this small-molecule approach in collaboration with Sum-
mit Therapeutics. We set up a screen in an mdx cell line
for molecules that would increase the transcription of utro-
phin.71 This screen has led to the development of a first-in-
class drug (SMTC1100) for the modulation of utrophin;
this drug has just completed a phase 1 trial in DMD pa-
tients and is now moving into phase 2 trials.72 More
recently, from this screen we characterized another mole-
cule that increases utrophin levels more than SMTC1100
and has better pharmokinetics. Pre-clinical data from an422 The American Journal of Human Genetics 98, 419–426, March 3mdx trial of one of these molecules, SMT022357, show
that daily treatment with the drug results in higher utro-
phin and dystroglycan levels in skeletal muscle. We have
shown significant improvement in the ability of mdx
mice to recover from eccentric contractions, a marker of
muscle function.73 Consistent with this, we observed a sig-
nificant reduction in fiber regeneration, particularly in the
diaphragm. These results highlight the efficient distribu-
tion of the drug and the positive systemic effect of this
utrophin-modulation strategy (for a review, see Guiraud
et al.5). We have also developed new cell-line screens
from which we are developing other lead candidates that
act differently than SMTC1100 and SMT022357. Thus,
we have a very promising molecule in phase 2 trials and
are following up on other lead compounds for DMD ther-
apy using utrophin modulation.
Several other approaches forDMD therapy that target the
primary causeof thedisease aremaking significantprogress.
Readthrough of stop codons has produced the paradigm for
clinical trials,74 and the first drug using this approach, ata-
luren, has recently received a conditionalmarketing autho-
rization in Europe. Exon 51 skipping looks promising, and
clinical trials are ongoing. Both Prosensa NV/BioMarin
and Sarepta Therapeutics have filed nondisclosure agree-
ments recently for their exon-51-skipping therapies drisa-
persen75 and eteplirsen, respectively.76 However, these
drugs only tackle the problem in a small fraction of the
13% of patients who have mutations treatable by exon 51
skipping because patients need to be ambulant for entry
into any trial. Current constructs for exon skipping do not
enter the heart, and other exons need to be and are being
targeted. Their efficacy also needs to be improved. Multi-
exon-skipping strategies might be more widely applicable
but are in their infancy.77 As this review goes to press, the
FDA is considering approval of submissions from com-
panies involved in exon skipping. The effects reported
thus far are small, and further trials are needed to demon-
strate that enough dystrophin is produced to provide a clin-
ically meaningful effect. Nevertheless, proof of principle
has been shown, and next-generation exon-skipping
chemistry, such as the tricyloDNA chemistry,78 should
provide better efficacy. Gene therapy delivering minigenes
is progressing well and has shown promising data in
dogs without immunosuppression.79 Current challenges
include delivery, obtaining high titers of virus, and safety
of systemic delivery. Stem cell strategies could have long-
term value, and approaches using CRISPR/Cas9 are rapidly
being explored but ultimately will require viral delivery.80
These genetic approaches can be used in conjunction
with pharmacological approaches that slow the progres-
sion of the disease; combination therapy could ultimately
provide the best strategy for treating patients.70,81
Progress in the development of the diagnosis and
treatment of DMD has very much depended on close
collaboration among scientists, clinicians, and patients.
The continued support of major Duchenne charities (the
UK Muscular Dystrophy and US Muscular Dystrophy, 2016
Association) and the regular interaction with patients and
their families have played a very important role in my
career and the progress that has been made. In the future,
it will be even more important to involve patients in the
design and development of therapies to ensure that pa-
tients can benefit maximally from any approach. DMD is
a complex disease with a lot of variation in its progression
between patients. It will be important to develop patient-
focused therapies depending on the stage of the disease
progression and the age of the patient.
Much of the progress in DMD has depended on tech-
nical innovation (PCR, development of gene-therapy vec-
tors, exon-skipping chemistry), and further developments
in biomarkers are needed. There will also be innovation in
monitoring patients’ responses and adverse events. This is
an exciting time in the translation of genetics and geno-
mics into effective treatments. What I thought was impos-
sible 20 years ago is now very close to reality. The dream of
an effective treatment of DMD, and with it treatments for
other rare diseases, will soon be realized.Acknowledgments
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